Related Experiment Video
Updated: Feb 26, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution
Federico Pessina1, Pierina Navarria2, Luca Cozzi2,3
1Neurosurgery Oncology Department, Istituto Humanitas Cancer Center & Research Hospital, Rozzano, Italy.
Aim:
To evaluate the outcome of newly diagnosed anaplastic glioma patients treated in our institution in relation to the 2016 WHO classification suggestions.
Methods:
This retrospective study included patients who underwent surgery plus adjuvant chemotherapy alone or concomitant and adjuvant chemoradiotherapy. Response was recorded using the Response Assessment in Neuro-Oncology criteria.
Results:
123 patients were analyzed. The median progression-free survival time and the 2, 3 and 5 years progression-free survival rate were 27 months, 65.5, 21.2 and 21.2%; the 2, 3 and 5 years overall survival rate were 89.7, 83.0 and 58.4%. From the univariate/multivariate analysis, the factors conditioning survival were Karnofsky performance scale, extent of resection, IDH1 mutation status and presence of 1p/19q codeletion.
Conclusion:
The choice of adjuvant treatment have to consider molecular assessment and, in our experience, the extent of surgical resection.
